PHPMem v2.0.1

Version
1.6.45
Uptime
15 days 12 hours 53 minutes 49 seconds

Memory

Total
512MB
Used
9,60MB (1.88%)
Free
502,40MB

Keys

Current
11 839
Total (since start)
35 066
Evictions
0
Reclaimed
734
Expired Unfetched
0
Evicted Unfetched
0

Connections

Current
14 / 1 024 max
Total
174 052
Rejected
0
llm:041616f34755fefc18900bab3c36529fa77e0660e277259393dacce5dd84217b
TTL 15 hours 22 minutes 15 seconds Size 2,16KB Export
Edit
```json { "proposals": [ { "join_class": "temporal", "column": "ae.AEDTC", "kind": "external_candidate", "entry_id": null, "name": "FDA Drug Approval Dates", "probable_url": "https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files", "license_expectation": "Public Domain (US Government)", "join_story": "Joining adverse event dates to FDA approval timelines would reveal whether events cluster in early post-approval periods versus mature drug lifecycles, helping distinguish launch-phase surveillance signals from long-term safety patterns.", "teaches": "Whether your adverse events concentrate in newly approved drugs or established therapies, informing risk monitoring priorities." }, { "join_class": "category", "column": "ae.AEACN", "kind": "external_candidate", "entry_id": null, "name": "MedDRA Hierarchy Reference", "probable_url": "https://www.meddra.org/how-to-use/support-documentation/english", "license_expectation": "Restricted - requires subscription", "join_story": null, "teaches": null } ] } ``` Wait, I need to reconsider. MedDRA requires subscription access, which violates the "public, credential-free" requirement. Let me revise: ```json { "proposals": [ { "join_class": "temporal", "column": "ae.AEDTC", "kind": "external_candidate", "entry_id": null, "name": "FDA Drug Approval Dates", "probable_url": "https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files", "license_expectation": "Public Domain (US Government)", "join_story": "Joining adverse event dates to FDA approval timelines would reveal whether events cluster in early post-approval periods versus mature drug lifecycles, helping distinguish launch-phase surveillance signals from long-term safety patterns.", "teaches": "Whether your adverse events concentrate in newly approved drugs or established therapies, informing risk monitoring priorities." } ] } ```